Analyst Price Target is $18.50
▲ +82.09% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for aTyr Pharma in the last 3 months. The average price target is $18.50, with a high forecast of $21.00 and a low forecast of $15.00. The average price target represents a 82.09% upside from the last price of $10.16.
Current Consensus is
The current consensus among 6 investment analysts is to buy stock in aTyr Pharma. This rating has held steady since February 2020, when it changed from a Hold consensus rating.
aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel immunological pathways. Its product pipeline include ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1;DARS-1(3). The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.